ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $79,004 | $64,884 | $30,433 | $6,434 |
| G&A Expenses | $15,304 | $9,706 | $6,473 | $0 |
| SG&A Expenses | $15,304 | $9,706 | $6,473 | $2,262 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $94,308 | $74,590 | $36,906 | $8,696 |
| Operating Income | -$94,308 | -$74,590 | -$36,906 | -$8,696 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $13,820 | $5,257 | $0 | -$42,910 |
| Pre-Tax Income | -$80,488 | -$69,333 | -$36,906 | -$51,606 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$80,488 | -$69,333 | -$36,906 | -$51,606 |
| % Margin | – | – | – | – |
| EPS | -2.56 | -2.17 | -1.1 | -40.44 |
| % Growth | -18% | -97.3% | 97.3% | – |
| EPS Diluted | -2.56 | -2.17 | -1.1 | -40.44 |
| Weighted Avg Shares Out | 31,469 | 31,957 | 33,494 | 1,276 |
| Weighted Avg Shares Out Dil | 31,469 | 31,957 | 33,494 | 1,276 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,820 | $5,257 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $36,906 | $0 |
| EBITDA | -$80,488 | -$74,590 | $0 | -$51,606 |
| % Margin | – | – | – | – |